The market for biomaterials in gene therapy is experiencing robust growth, driven by advancements in genetic engineering and the rising prevalence of genetic disorders. According to a report by Allied Market Research, the global gene therapy market is projected to reach $6.21 billion by 2026, growing at a CAGR of 33.6% from 2019 to 2026. The development of innovative biomaterial based vectors for safer and more efficient delivery of therapeutic genes is a key market stimulator. While technical challenges and regulatory hurdles exist, the potential of gene therapies in treating currently incurable diseases presents immense market opportunities.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by